Today: 2 July 2026
Browse Category

NYSE:LLY 21 January 2026 - 31 January 2026

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

Healthcare stocks hold up as Lilly’s $3.5 billion plant plan hits tape; biotech bruised

New York, Jan 31, 2026, 13:49 EST — Market closed. Healthcare shares ended Friday stronger than the wider market following Eli Lilly’s announcement of a $3.5 billion manufacturing facility in Pennsylvania dedicated to injectable weight-loss drugs. CEO David Ricks described the new plant as “really state of the art manufacturing to last many decades to come” during a press briefing.
31 January 2026
······
Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

Eli Lilly stock price (LLY): $3.5B plant, EU Mounjaro call and earnings ahead — what to watch

New York, Jan 31, 2026, 09:59 EST — The market has closed. Shares of Eli Lilly finished Friday up about 1.3%, closing at $1,037.15. The boost came after the company unveiled a $3.5 billion plan for a new manufacturing facility in Pennsylvania. This plant will produce injectable weight-loss drugs, including retatrutide—a next-gen medication Lilly says has outperformed Zepbound. “All these sites, including this one, will be really state of the art manufacturing to last many decades to come,” CEO David Ricks said in Allentown. Drugmakers like Pfizer and Merck & Co are also expanding U.S. capacity amid Donald Trump’s threat of import tariffs. Meanwhile, Lilly is racing Novo Nordisk for U.S. approval of an oral weight-loss pill, which it plans to price at $150 a month and launch in several countries.
31 January 2026
···
Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

Eli Lilly stock price today: LLY rises on $1.93 billion Repertoire deal as earnings near

New York, Jan 29, 2026, 11:20 ET — During the regular session Eli Lilly shares climbed Thursday after Repertoire Immune Medicines announced a partnership with the drugmaker worth up to $1.93 billion, including an $85 million upfront payment, plus milestone and royalty fees. Lilly was up 0.5% at $1,028.89 in late morning trading, while the S&P 500 slipped about 1.4%. Repertoire will lead early research using its Decode platform, which explores how T cells attack diseased cells, before Lilly takes the programs to the clinic and eventually the market.
29 January 2026
····
Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

Eli Lilly stock price falls over 2% as Medicare puts Trulicity on 2028 price-talk list

New York, January 27, 2026, 18:39 EST — After-hours Eli Lilly and Company shares ended Tuesday down $24.22, or roughly 2.3%, at $1,039.51. In after-hours trading, the stock edged up about 0.3% to $1,042.50. The U.S. Centers for Medicare & Medicaid Services announced it selected Lilly’s Trulicity, a type 2 diabetes drug, along with 14 other medicines for 2028 price negotiations. This marks the first time the list includes some therapies covered under Medicare Part B. Last year, the agency projected that negotiated prices for the 15 drugs chosen for 2027 would cut annual spending by 36%, roughly $8.5 billion, compared to recent costs.
28 January 2026
·······
1 2 3 4 5 6 … 13

Stock Market Today

  • Cramer’s Top 10: Jobs Miss, Upgrades for Palantir and Airlines, OpenAI’s Government Plan
    July 2, 2026, 9:20 AM EDT. Jim Cramer's July 2 watchlist points to a lighter-than-forecast June jobs report-nonfarm payrolls up just 57,000, well below the 115,000 expected. That pushed Treasury yields lower and futures up. OpenAI is reportedly offering the U.S. government a 5% stake to let it in on AI gains. Palantir saw DA Davidson boost the stock to buy, setting a target for 40% upside. Nvidia is rolling out a model where AI startups get compute power in exchange for a piece of revenue. Meta laid out fresh plans for cloud AI. Honeywell Aerospace, Delta, and United picked up upgrades as supply and fuel costs improved. DuPont's price target saw a small bump.
Go toTop